Skip to main content
. 2017 Jan 6;4(1):1–7. doi: 10.1007/s40801-016-0102-5

Fig. 2.

Fig. 2

Progression-free survival from initiation of pertuzumab (Kaplan–Meier analysis)—sensitivity analysis population